Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1121-1140 of 2,251 trials

Obsessive-Compulsive Disorder: Pramipexole Treatment Study

We are investigating whether pramipexole can improve treatment outcomes for individuals with resistant OCD. The study will also assess the safety of this medication and its effects on brain function.

Obsessive-Compulsive Disorder (OCD)6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

B-Cell Blood Cancers: AZD5492 Treatment Study

We are investigating whether AZD5492 is safe and effective for adults with relapsed or refractory B-cell malignancies, both on its own and with other cancer treatments.

B-Cell Malignancies>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Chronic Myelomonocytic Leukemia: New Treatment Combination Study

We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.

Chronic Myelomonocytic Leukemia1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesHematologyOncology

Calcium Absorption: Glycocholate and Butyrate Study

We are testing the safety and tolerability of glycocholate and butyrate in healthy women who have undergone Roux-en-Y gastric bypass. This study aims to see if these substances can help improve calcium absorption.

Postoperative Obesity≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

Advanced CancerSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Crizotinib Safety Study for Cancer Patients

We are monitoring the safety of crizotinib for individuals who have participated in earlier studies. This research aims to ensure the continued well-being of patients using this treatment.

Solid TumorMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Immunotherapy and Chemotherapy Study

We are studying a treatment combining immunotherapy, chemotherapy, and radiotherapy for patients with newly diagnosed non-small cell lung cancer that has spread to a few other areas. The aim is to see if this approach helps patients live longer without their cancer worsening.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Triple Negative Breast Cancer: Imatinib Study

We are investigating whether Imatinib can convert triple negative breast cancer into a more treatable ER-positive type. The study also examines the safety of the drug and its effects on related cancer markers.

Triple Negative Breast CancerPrimary Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Capsaicin for Finger Pain in Osteoarthritis

We are studying whether a stronger capsaicin cream can reduce finger pain better than a lower dose in people with digital osteoarthritis. This trial also examines its effects on daily function and overall quality of life.

Finger Osteoarthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesRheumatology

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Childhood Cancer: Vaccine Response Study for Measles and Chickenpox

We are examining how well children and teens with a history of childhood cancer respond to vaccines for measles and chickenpox after treatment. This study aims to understand their immunity levels and how treatment affects their ability to fight these diseases.

Pediatric Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOncologyPediatrics

Multiple Myeloma: Anitocabtagene Autoleucel Study

We are comparing a new treatment called anitocabtagene autoleucel with standard therapies for patients with relapsed or refractory multiple myeloma. The goal is to see which option works better and is safer for patients.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

HIV Treatment: Combination Therapy Study

We are investigating a combination of three drugs to see if they can help reactivate HIV in people living with the virus. This study aims to understand the safety and effectiveness of these treatments.

HIV-1≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study

We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.

Familial Amyloid PolyneuropathyConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Solid Tumors: NECVAX-NEO1 with PD-1/PD-L1 Therapy

We are studying a new treatment, NECVAX-NEO1, for patients with solid tumors already on PD-1 or PD-L1 therapy. The trial aims to assess its safety and how well it may work in combination with existing treatments.

Advanced Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Carpal Tunnel Syndrome: Injection vs. Surgery

We are comparing the effectiveness of ultrasound-guided injections to surgery for treating carpal tunnel syndrome. This study will help determine which approach may be better for patients in the long run.

Carpal Tunnel Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Glioblastoma: Meclofenamate with Temozolomide

We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.

Glioblastoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology